Camila Coelho, PhD, MBA, Named Rising Star by Union of Immunological Societies
Mount Sinai faculty earns an esteemed prize for early-stage researchers who are revolutionizing the field
The International Union of Immunological Societies (IUIS) has named Camila Coelho, PhD, MBA, Assistant Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, as one of its 2025 IUIS Rising Stars. The IUIS Early Career Committee bestows this esteemed prize to early-stage researchers who are revolutionizing immunology through high-impact, creative research.
Within Mount Sinai’s Center for Vaccine Research and Pandemic Preparedness, Dr. Coelho is the head of the Coelho Lab, where she and her team study human B cell responses to infections and vaccines against emerging pathogens. Her aim is to acquire a better understanding of the immunological processes that underlie defense against newly developing viral illnesses such as Mpox, by combining experimental and bioinformatics methods.
"Dr. Coelho is a pioneering immunologist whose work at the intersection of human immunology, computational biology, and vaccines is significantly improving global health," said Ana Fernandez-Sesma, PhD, Chair of the Department of Microbiology at the Icahn School of Medicine. "The IUIS's designation of her as a 2025 Rising Star is evidence of her scientific vision and dedication to the advancement of translational immunology."
Dr. Coelho was involved in groundbreaking research in human vaccine immunology before joining Mount Sinai, and she is still studying how antibody responses and B cell memory change after vaccination and illness. Her research directly affects the development of next-generation vaccination plans and the effectiveness of vaccines.
Dr. Coelho began her studies in Brazil and her postdoctoral trainings were carried out at the La Jolla Institute for Immunology, the National Institute of Allergy and Infectious Diseases and Georgetown University.
Dr. Coelho is one of just a few early-career scientists worldwide who have been honored by the IUIS for advancing immunology research and exhibiting leadership potential in the field. Go to www.coelholab.com to find out more about the studies conducted by the Coelho lab.
Visit https://iuis.org/news/meet-the-iuis-2025-rising-stars for additional details about the IUIS Rising Stars program and the entire 2025 cohort.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
Icahn School of Medicine at Mount Sinai Remains Among Top Institutions for NIH Funding
Mar 05, 2026 View All Press Releases
Spain Honors Ana Fernandez-Sesma, PhD, Chair of Mount Sinai’s Department of Microbiology
Jul 21, 2023 View All Press Releases